For the Inventor, By the Inventor

Enter assignee name

Constance, Germany

Takeda Gmbh

USPTO Granted Patents = 47

% Expired Patents = 61.7

CIPO Patents = 10

EPO Patents = 30

Trademarks = 12

Forward Citations = 221

Loading Chart...

Loading Chart...

121 inventors (with patents filed for the assignee):

Beate Schmidt (10 out of 29 patents)

Ulrich Kautz (8 out of 21 patents)

Degenhard Marx (8 out of 15 patents)

4. Torsten Dunkern (6 out of 6 patents)

5. Christof Zitt (6 out of 9 patents)

6. Armin Hatzelmann (6 out of 20 patents)

7. Rango Dietrich (5 out of 30 patents)

8. Hans-Peter Kley (5 out of 17 patents)

9. Guido Hanauer (4 out of 6 patents)

10. Hartmut Ney (4 out of 12 patents)

11. Geert Jan Sterk (4 out of 28 patents)

12. Josef Stadlwieser (4 out of 8 patents)

13. Heiko Bernsmann (4 out of 4 patents)

14. Andreas Pahl (4 out of 12 patents)

15. Rolf-Peter Hummel (4 out of 12 patents)

Core Competencies:

GM-CSF Neutralizing Compound

PDE4 Inhibitors

Nonalcoholic Fatty Liver Disease

Idiopathic Pulmonary Fibrosis

Roflumilast

Ciclesonide

Methylpyrrolopyrimidinecarboxamides

Lyophilized Formulation

Aerosolization Apparatus

Oral Dosage Form

Hydroxy-6-Heteroarylphenanthridines

Pyrazolone Derivatives

47 patents: Sort by Forward Citations

1. 11690839 - Treatment of idiopathic pulmonary fibrosis (2023-07-04),

2. 11179384 - Treatment of nonalcoholic fatty liver disease (2021-11-23),

3. 11173208 - Liquid formulation comprising GM-CSF neutralizing compound (2021-11-16),

4. 10758621 - Liquid formulation comprising GM-CSF neutralizing compound (2020-09-01),

5. 10745475 - Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics (2020-08-18),

6. 10495630 - Methods for the determination of compounds or compositions for the treatment of lipofuscin related diseases and compounds or compositions (2019-12-03),

7. 9962377 - Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors (2018-05-08),

8. 9919051 - Liquid formulation comprising GM-CSF neutralizing compound (2018-03-20),

9. 9833410 - Lyophilized formulation comprising GM-CSF neutralizing compound (2017-12-05),

10. 9545490 - Apparatus for the aerosolization of large volumes of dry powder (2017-01-17),

11. 9422327 - Process for preparing crystalline ciclesonide with defined particle size (2016-08-23),

12. 9387205 - Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors (2016-07-12),

13. 9376442 - Methylpyrrolopyrimidinecarboxamides (2016-06-28),

14. 9340522 - Pyrazolone-derivatives and their use as PDE-4 inhibitors (2016-05-17),

15. 9309187 - EP2 receptor agonists (2016-04-12),

Company Overview

Takeda GmbH, based in Constance, Germany, is a prominent player in the biopharmaceutical sector, focusing on innovative therapies for serious health conditions. The company specializes in developing treatments for idiopathic pulmonary fibrosis and nonalcoholic fatty liver disease, among other chronic diseases. Its research encompasses a range of therapeutic areas, including pulmonary hypertension and diabetes mellitus type 2, leveraging advanced technologies such as GM-CSF neutralizing compounds and PDE4 inhibitors to address unmet medical needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

47 Patents

#4 in Constance

#1,126 in Germany

#14,827 in the World

Constance, Germany

Takeda Gmbh

Forward Citations = 221

121 inventors:

Beate Schmidt (10 out of 29 patents)

Ulrich Kautz (8 out of 21 patents)

Degenhard Marx (8 out of 15 patents)

4. Torsten Dunkern (6 out of 6 patents)

5. Christof Zitt (6 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Takeda Gmbh. Retrieved from https://idiyas.com/company/takeda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…